Distinguished in D-Minus Hemolytic Uremic Syndrome

Doyeun H. Oh

Songnam, KR 
Distinguished in D-Minus Hemolytic Uremic Syndrome
Songnam, KR 
OverviewLocationsClinical Research

Overview

Doyeun Oh practices in Songnam, Republic of Korea. Oh is rated as a Distinguished expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. Their top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), Thrombocytopenia, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Thrombectomy.

Their clinical research consists of co-authoring 84 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of D-Minus Hemolytic Uremic Syndrome.

Locations

Songnam, Republic of Korea
Other Locations
Gyeonggi-do, Republic of Korea
Seoul, Republic of Korea
Wondu, Republic of Korea
Gangwon Do, Republic of Korea
Pochon, 463712, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
Enrollment Status: Unknown
Publish Date: May 21, 2019
Intervention Type: Drug
Study Drugs: mFOLFOX6, CAPOX
Study Phase: Phase 3

84 Total Publications

Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH).
Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH).
Journal: Blood research
Published: July 11, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Oh's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile